Hostname: page-component-745bb68f8f-v2bm5 Total loading time: 0 Render date: 2025-01-08T08:07:01.419Z Has data issue: false hasContentIssue false
  • English
  • Français

A Comprehensive Assessment Across the Healthcare Continuum: Risk of Hospital-Associated Clostridium difficile Infection Due to Outpatient and Inpatient Antibiotic Exposure

Published online by Cambridge University Press:  21 September 2015

Sara Y. Tartof ,
Gunter K. Rieg ,
Rong Wei ,
Hung Fu Tseng ,
Steven J. Jacobsen  and
Kalvin C. Yu
Sara Y. Tartof*
Affiliation:
Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California
Gunter K. Rieg
Affiliation:
Department of Infectious Diseases, Southern California Permanente Medical Group, Harbor City, California
Rong Wei
Affiliation:
Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California
Hung Fu Tseng
Affiliation:
Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California
Steven J. Jacobsen
Affiliation:
Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California
Kalvin C. Yu
Affiliation:
Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California Department of Medicine, Infectious Disease/Infection Control, New York University School of Medicine, New York, New York
*
Address correspondence to Sara Y. Tartof, PhD, Department of Research and Evaluation, Kaiser Permanente Southern California, 100 S Los Robles, 2nd Fl, Pasadena, CA 91101 ([email protected]).
Get access Rights & Permissions [Opens in a new window]

Abstract

BACKGROUND

Limitations in sample size, overly inclusive antibiotic classes, lack of adjustment of key risk variables, and inadequate assessment of cases contribute to widely ranging estimates of risk factors for Clostridium difficile infection (CDI).

OBJECTIVE

To incorporate all key CDI risk factors in addition to 27 antibiotic classes into a single comprehensive model.

DESIGN

Retrospective cohort study.

SETTING

Kaiser Permanente Southern California.

PATIENTS

Members of Kaiser Permanente Southern California at least 18 years old admitted to any of its 14 hospitals from January 1, 2011, through December 31, 2012.

METHODS

Hospital-acquired CDI cases were identified by polymerase chain reaction assay. Exposure to major outpatient antibiotics (10 classes) and those administered during inpatient stays (27 classes) was assessed. Age, sex, self-identified race/ethnicity, Charlson Comorbidity Score, previous hospitalization, transfer from a skilled nursing facility, number of different antibiotic classes, statin use, and proton pump inhibitor use were also assessed. Poisson regression estimated adjusted risk of CDI.

RESULTS

A total of 401,234 patients with 2,638 cases of incident CDI (0.7%) were detected. The final model demonstrated highest CDI risk associated with increasing age, exposure to multiple antibiotic classes, and skilled nursing facility transfer. Factors conferring the most reduced CDI risk were inpatient exposure to tetracyclines and first-generation cephalosporins, and outpatient macrolides.

CONCLUSIONS

Although type and aggregate antibiotic exposure are important, the factors that increase the likelihood of environmental spore acquisition should not be underestimated. Operationally, our findings have implications for antibiotic stewardship efforts and can inform empirical and culture-driven treatment approaches.

Infect. Control Hosp. Epidemiol. 2015;36(12):1409–1416

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 36 , Supplement 12 , December 2015 , pp. 1409 - 1416
Copyright
© 2015 by The Society for Healthcare Epidemiology of America. All rights reserved 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. Lucado, J, Gould, C, Elixhauser, A. Clostridium difficile infections (CDI) in hospital stays, 2009: statistical brief #124. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs . Rockville, MD: Agency for Healthcare Research and Quality; 2006.Google Scholar
2. McDonald, LC, Killgore, GE, Thompson, A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile . N Engl J Med 2005;353:2433–2441.Google Scholar
3. Loo, VG, Poirier, L, Miller, MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile–associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442–2449.Google Scholar
4. Kyne, L, Sougioultzis, S, McFarland, LV, Kelly, CP. Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea. Infect Control Hosp Epidemiol 2002;23:653–659.Google Scholar
5. Lessa, FC, Gould, CV, McDonald, LC. Current status of Clostridium difficile infection epidemiology. Clin Infect Dis 2012;55:S65–S70.CrossRefGoogle ScholarPubMed
6. Stevens, V, Dumyati, G, Fine, LS, Fisher, SG, van Wijngaarden, E. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis 2011;53:42–48.CrossRefGoogle ScholarPubMed
7. Owens, RC Jr, Donskey, CJ, Gaynes, RP, Loo, VG, Muto, CA. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008;46:S19–S31.Google Scholar
8. Pakyz, AL, Jawahar, R, Wang, Q, Harpe, SE. Medication risk factors associated with healthcare-associated Clostridium difficile infection: a multilevel model case-control study among 64 US academic medical centres. J Antimicrob Chemother 2014;69:1127–1131.Google Scholar
9. Slimings, C, Riley, TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother 2014;69:881–891.CrossRefGoogle ScholarPubMed
10. Doernberg, SB, Winston, LG, Deck, DH, Chambers, HF. Does doxycycline protect against development of Clostridium difficile infection? Clin Infect Dis 2012;55:615–620.CrossRefGoogle ScholarPubMed
11. Park, SW, Choi, AR, Lee, HJ, et al. The effects of statins on the clinical outcomes of Clostridium difficile infection in hospitalised patients. Aliment Pharmacol Ther 2013;38:619–627.Google Scholar
12. Baxter, R, Ray, GT, Fireman, BH. Case-control study of antibiotic use and subsequent Clostridium difficile–associated diarrhea in hospitalized patients. Infect Control Hosp Epidemiol 2008;29:44–50.CrossRefGoogle ScholarPubMed
13. Dubberke, ER, Butler, AM, Yokoe, DS, et al. Multicenter study of surveillance for hospital-onset Clostridium difficile infection by the use of ICD-9-CM diagnosis codes. Infect Control Hosp Epidemiol 2010;31:262–268.CrossRefGoogle ScholarPubMed
14. Moehring, RW, Lofgren, ET, Anderson, DJ. Impact of change to molecular testing for Clostridium difficile infection on healthcare facility-associated incidence rates. Infect Control Hosp Epidemiol 2013;34:1055–1061.Google Scholar
15. Dial, S, Alrasadi, K, Manoukian, C, Huang, A, Menzies, D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004;171:33–38.CrossRefGoogle ScholarPubMed
16. Hensgens, MP, Goorhuis, A, Dekkers, OM, Kuijper, EJ. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother 2012;67:742–748.Google Scholar
17. McCusker, ME, Harris, AD, Perencevich, E, Roghmann, MC. Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerg Infect Dis 2003;9:730–733.Google Scholar
18. Vesta, KS, Wells, PG, Gentry, CA, Stipek, WJ. Specific risk factors for Clostridium difficile-associated diarrhea: a prospective, multicenter, case control evaluation. Am J Infect Control 2005;33:469–472.Google Scholar
19. Kuntz, JL, Polgreen, PM. The importance of considering different healthcare settings when estimating the burden of Clostridium difficile . Clin Infect Dis 2015;60:831–836.Google Scholar
20. Tartof, SY, Yu, KC, Wei, R, Tseng, HF, Jacobsen, SJ, Rieg, GK. Incidence of polymerase chain reaction-diagnosed Clostridium difficile in a large high-risk cohort, 2011–2012. Mayo Clin Proc 2014;89:1229–1238.Google Scholar
21. Koebnick, C, Langer-Gould, AM, Gould, MK, et al. Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data. Perm J 2012;16:37–41.Google Scholar
22. McDonald, LC, Coignard, B, Dubberke, E, et al. Recommendations for surveillance of Clostridium difficile–associated disease. Infect Control Hosp Epidemiol 2007;28:140–145.Google Scholar
23. Centers for Disease Control and Prevention. Multidrug-Resistant Organisms and Clostridium difficile Infection (MDRO/CDI) Module. Atlanta: National Healthcare Safety Network 2013.Google Scholar
24. Charlson, ME, Pompei, P, Ales, KL, MacKenzie, CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–383.Google Scholar
25. He, M, Miyajima, F, Roberts, P, et al. Emergence and global spread of epidemic healthcare-associated Clostridium difficile . Nat Genet 2013;45:109–113.Google Scholar
26. Nicolle, LE, Bentley, DW, Garibaldi, R, Neuhaus, EG, Smith, PW. Antimicrobial use in long-term-care facilities. SHEA Long-Term-Care Committee. Infect Control Hosp Epidemiol 2000;21:537–545.CrossRefGoogle ScholarPubMed
27. Buffie, CG, Bucci, V, Stein, RR, et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile . Nature 2014;517:205–208.Google Scholar
28. Longtin, Y, Trottier, S, Brochu, G, et al. Impact of the type of diagnostic assay on Clostridium difficile infection and complication rates in a mandatory reporting program. Clin Infect Dis 2013;56:67–73.Google Scholar
29. Planche, TD, Davies, KA, Coen, PG, et al. Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C difficile infection. Lancet Infect Dis 2013;13:936–945.Google Scholar
Supplementary material: File

Tartof supplementary material

Appendix 1

Download Tartof supplementary material(File)
File 21.8 KB